Related references
Note: Only part of the references are listed.Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes
Caroline A. Nelson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer A Systematic Review
Maria S. Asdourian et al.
JAMA DERMATOLOGY (2022)
Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients
Kevin Sheng-Kai Ma et al.
OCULAR SURFACE (2021)
The role of T cells in pemphigus vulgaris and bullous pemphigoid
Hui Fang et al.
AUTOIMMUNITY REVIEWS (2020)
Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature
Noa Kremer et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Genetics and Omics Analysis of Autoimmune Skin Blistering Diseases
Michael Olbrich et al.
FRONTIERS IN IMMUNOLOGY (2019)
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi et al.
JAMA ONCOLOGY (2019)
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
Adriana T. Lopez et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy
Leo L. Wang et al.
JAMA DERMATOLOGY (2018)
The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-induced Tissue injury
Hui Fang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment
Philippe Bernard et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2017)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Toxicities of Immunotherapy for the Practitioner
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Mitigating the toxic effects of anticancer immunotherapy
Tara C. Gangadhar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Inessa Schwab et al.
NATURE REVIEWS IMMUNOLOGY (2013)
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
Kim L. Good-Jacobson et al.
NATURE IMMUNOLOGY (2010)
Share Paper
